POLITICS

Trump Orders Federal Rescheduling To Expand Cannabis Research

PUBLISHED Dec 18, 2025, 4:06 PM ET

Read, Watch or Listen

Trump Orders Federal Rescheduling To Expand Cannabis Research

Media Bias Meter

Sources: 9

Center 100%

Sources: 9

Washington, President Donald Trump signed an executive order Thursday directing federal agencies to expedite reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act. Officials said the change recognizes medical use and will ease research barriers, banking access, and tax treatment such as 280E relief. State researchers and attorneys general offered mixed reactions, noting potential benefits for clinical studies and continued regulatory constraints, heightened federal oversight. Cannabis companies and payment firms welcomed the move, citing improved operations and investment prospects. The executive order does not legalize recreational use. Based on 6 articles reviewed and supporting research.

By James Porter | JQJO News

Timeline of Events

November 12, 2025 — Federal clarification issued on hemp-derived intoxicants.
December 18, 2025 — President signs executive order directing expedited rescheduling to Schedule III.
December 18, 2025 — Corporations (FLUENT, POSaBIT) issue supportive press releases.
December 18–19, 2025 — Local researchers and state officials comment on research opportunities and regulatory limits.
Post-signature — Attorneys general and legal actors indicate potential challenges and extended administrative procedure.

Media Bias

Articles Published:: 9
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 9

Who Benefited

Licensed cannabis companies, payment processors, investors, medical researchers, patients seeking clinical trials, and banks are likely to see reduced regulatory barriers, improved access to financial services, and potential tax relief following the rescheduling directive.

Who Impacted

Some state officials, law enforcement stakeholders, and opponents of cannabis liberalization may face increased pressure and legal challenges as federal guidance shifts, prompting debates over public health, enforcement, and youth access.

Media Bias